Obseva Provides Update News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Obseva provides update. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Obseva Provides Update Today - Breaking & Trending Today

Investegate |ObsEva SA Announcements | ObsEva SA: ObsEva Provides Update on EU Marketing Authorisation Process for Linzagolix, an Oral GnRH Antagonist, for the Treatment of Uterine Fibroids

Investegate announcements from ObsEva SA, ObsEva Provides Update on EU Marketing Authorisation Process for Linzagolix, an Oral GnRH Antagonist, for the Treatment of Uterine Fibroids ....

United States , Shauna Dillon , Exchange Commission , Kissei Pharmaceutical Co Ltd , European Medicines Agency , Drug Administration , Swiss Exchange , Obseva Provides Update , Authorisation Process , New Drug Application , United States Food , Nasdaq Global Select Market , Private Securities Litigation Reform Act , Risk Factors , Annual Report , Investegate Announcements , Investegate Company Announcements , Obseva Sa , Lobenewswire And Globenewswire ,

Investegate |ObsEva SA Announcements | ObsEva SA: ObsEva Provides Update on Yselty® (Linzagolix) Clinical Development Program

ObsEva Provides Update on Yselty® (Linzagolix) Clinical Development Program

- European Medicines Agency Validates Yselty MAA for Uterine Fibroids; US NDA Planned for 1H 2021
- Phase 3 EDELWEISS 3 (Conducted in Europe and US) Study of Yselty for Treatment of Endometriosis is Progressing as Planned; Primary Endpoint Readout Expected 4Q 2021
- Phase 3 EDELWEISS 2 (Conducted in the United States) Yselty Endometriosis Study Discontinued Due to Enrollment Challenges; No Safety Concerns Identified

GENEVA, Switzerland and BOSTON, MA (Jan 11, 2021) – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, today announced several important updates on its Yselty program. ....

United States , Shauna Dillon , Brian Ocallaghan , Exchange Commission , Linzagolix Clinical Development Program , European Medicines Agency , Swiss Exchange , European Medicines Agency Validates Yselty , Obseva Provides Update , Clinical Development Program , Medicines Agency Validates Yselty , Uterine Fibroids , Primary Endpoint Readout Expected , Yselty Endometriosis Study Discontinued Due , Enrollment Challenges , Marketing Authorization Application , Elizabeth Garner , Chief Medical Officer , Development Program , Endometriosis Associated Pain , Briano Callaghan , Nasdaq Global Select Market , Note Regarding Forward Looking Statements , Private Securities Litigation Reform Act , Risk Factors , Annual Report ,